The California-based precision oncology firm Guardant Well being has struck a deal to advertise its vary of liquid and tissue biopsy checks for most cancers screening throughout the Center East and North African markets.
Partnering with the multinational pharmaceutical firm Hikma Prescribed drugs, the partnership plans to market Guardant Well being’s recurrence monitoring and tumour mutation profiling throughout all stable cancers in nations all through the area.
The partnership consists of Guardant Well being’s merchandise resembling Defend take a look at for most cancers screening and detection, Guardant Reveal for illness detection,Guardant360 and its variant TissueNext, which is meant for genomic profiling throughout all stable cancers.
Simranjit Singh, Guardant Well being Europe, the Center East and Africa (AMEA) CEO, stated: “At this time, an growing variety of sufferers with most cancers are being detected on the superior stage, making it extra essential to match these sufferers to acceptable therapies in a well timed method. Finally, our purpose is to make most cancers screening simple and efficient in order that we will detect most cancers earlier when it’s most treatable.”
It comes amid a collection of worldwide expansions for Guardant Well being, with the corporate introducing its blood-based colorectal most cancers (CRC) screening take a look at Defend in South Korea in November 2023.
In Could final 12 months, the corporate additionally expanded into Singapore, receiving approval from the nation’s Well being and Sciences Authority to market its Guardant360 CDx liquid biopsy take a look at for sufferers with superior stable tumours.
Entry probably the most complete Firm Profiles
in the marketplace, powered by GlobalData. Save hours of analysis. Acquire aggressive edge.
Firm Profile – free
pattern
Your obtain electronic mail will arrive shortly
We’re assured in regards to the
distinctive
high quality of our Firm Profiles. Nonetheless, we wish you to take advantage of
useful
choice for your small business, so we provide a free pattern which you could obtain by
submitting the beneath kind
By GlobalData
Hikma’s government vice chairman Mazen Darwazah stated: “Our partnership with Guardant Well being provides next-generation sequencing diagnostics that may doubtlessly rework most cancers care within the Center East and North Africa bringing hope to sufferers going through this difficult journey. We’re excited to accomplice with Guardant Well being, as their providing can assist sufferers in any respect phases of the illness.”
In Could of 2021, Guardant Well being reported that its first blood-only liquid biopsy for detecting minimal residual illness (MRD) was capable of establish stage I-IV colorectal most cancers (CRC) sufferers with elevated danger of recurrence, with better sensitivity than earlier iterations.
